At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,174 enrolled
Drug / intervention
Rasagiline Mesylate +2 moredrug
Likely dose
Rasagiline Mesylate 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi Center, Double Blind, Randomized Start, Placebo-Controlled, Parallel-Group Study to Assess Rasagiline as a Disease Modifying Therapy in Early Parkinson's Disease Subjects
Teva Branded Pharmaceutical Products R&D, Inc.·interventional·Posted Nov 21, 2005·Updated Jan 12, 2012
In Brief
A Phase 3 clinical trial evaluating Rasagiline Mesylate and Placebo for Parkinson's Disease. Completed, enrolled 1,174 participants.
Detailed Summary
A 2 phase study to evaluate disease progression in Parkinson's disease patients taking rasagiline
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedNov 2005
Primary CompletionApr 2008
Study CompletionJun 2009
TodayJul 2026
First PostedNov 21, 2005
Enrollment StartNov 1, 2005
Primary CompletionApr 1, 2008
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.6 years ago
Interventions
Rasagiline Mesylatedrug
tablet, 1mg once daily
Rasagiline Mesylatedrug
tablet, 2mg once daily
Placeboother
Placebo